New York, Jan 14, 2026, 20:15 EST — Market closed
- Merck shares gained 2.5% on Wednesday, despite a weaker trend across U.S. markets
- Management is promoting a broader long-term growth path that extends beyond Keytruda
- Investors are shifting focus to Feb. 3 earnings to get clarity on the 2026 outlook and pipeline timing
Merck & Co (Merck & Company, Inc., MRK) shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading.
This move is crucial as Merck works to reshape the conversation about what will follow Keytruda, its top-selling drug, once competition heats up later this decade. Investors have viewed the looming “patent cliff” as both a science challenge and a hit to the company’s valuation.
Investors have been digging into management’s long-term projections at this week’s J.P. Morgan Healthcare Conference, where major pharma players usually lay out the year’s outlook. Merck’s message is straightforward: expand the core business, maintain steady cash flow, and steer clear of a steep fall once exclusivity ends.
Merck raised its forecast for newer growth drivers, expecting $70 billion in revenue from these areas by the mid-2030s as it aims to roll out more drugs ahead of mounting competition for Keytruda. The company now projects cardiometabolic and respiratory treatments will bring in about $20 billion, up from an earlier $15 billion estimate. Infectious-disease revenue forecasts jumped to around $15 billion from $5 billion.
Chief executive Rob Davis emphasized Merck’s strong deal-making firepower, assuring investors the company isn’t “limited from a balance sheet” perspective. He highlighted that Merck is actively seeking “strategic opportunity” and has capacity for deals in the “multi tens of billions of dollars” range. BioSpace
Merck gained ground even as the broader market slipped, with the S&P 500 falling 0.53% and the Dow dropping 0.09%. The stock outperformed major pharma rivals like Johnson & Johnson and Pfizer, while Eli Lilly retreated slightly. Trading volume in Merck shares was lighter than its recent average, according to a MarketWatch report.
Investors are being told to focus on the volume of shots on goal. Davis mentioned that Merck currently runs “80 phase three studies underway” — these late-stage trials usually back regulatory approvals — and linked the long-term target to a group of priority programs. PharmExec
Despite the stock’s bounce back, investors remain skeptical about whether the pipeline will produce actual launches instead of just presentations. Traders are focused on the same concerns: how much growth can come before Keytruda encounters tougher rivals, and how dependent that growth is on new deals.
There’s a riskier scenario. If crucial late-stage trials fail, deadlines get pushed back, or branded drug prices come under heavier pressure, Merck’s long-term goals could start to feel out of reach. On top of that, any major acquisition might face investor skepticism over whether the company paid too much.
Now that the U.S. market is closed, all eyes turn to Thursday’s open for any new analyst takes on Merck’s JPMorgan comments — and the next major event on the docket: Merck’s Q4 and full-year 2025 earnings call set for Feb. 3.
